NEW YORK, Dec. 19, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timelyinformation, WallStEquities.com has issued free tailored Stock Review on IMNP, ZGNX, SHPG, and MRK which is a click away at www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Immune Pharmaceuticals Inc.
On Monday, shares in Englewood Cliffs, New Jersey headquartered Immune Pharmaceuticals Inc. rose 0.35%, ending the day at $0.71. The stock recorded a trading volume of 343,986 shares. The Company's shares are trading below their 50-day moving average by 26.72%. Moreover, shares of Immune Pharmaceuticals, which develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology, have a Relative Strength Index (RSI) of 28.36.
On December 11th, 2017, Immune Pharmaceuticals announced that it has appointed John Zhang, MD, Ph.D. to the position of Vice President, R&D. Dr. Zhang will have oversight of the non-clinical aspects of the Company's drug development programs, including all pre-clinical studies, and will provide support for the clinical, regulatory, and manufacturing activities for its core pipeline assets, bertilimumab and nano-cyclosporin. Looking for insightful coverage on IMNP? Sign up for free at: www.wallstequities.com/registration/?symbol=IMNP
Shares in Emeryville, California headquartered Zogenix Inc. ended the day 1.19% higher at $38.20 with a total trading volume of 433,726 shares. In the last month and the previous three months, the stock has gained 3.95% and 162.54%, respectively. Additionally, the Company's shares have skyrocketed 214.40% on an YTD basis. The stock is trading above its 200-day moving average by 94.86%. Furthermore, shares of Zogenix, which develops and commercializes therapies for the treatment of central nervous system disorders in the US, have an RSI of 53.77.
On November 27th, 2017, research firm JMP Securities initiated a 'Market Outperform' rating on the Company's stock.
On December 04th, 2017 at the 71st American Epilepsy Society Annual Meeting, Zogenix announced new data from the Company's first Phase-3 trial (Study 1) of its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. The new Study 1 results showed that the odds of achieving a clinically meaningful (?50%) or substantial (?75%) reduction in convulsive seizure frequency were 29 and 50 times higher, respectively, among patients treated with ZX008 0.8 mg/kg/day than in patients treated with placebo. Today's complimentary research report on ZGNX is accessible at: www.wallstequities.com/registration/?symbol=ZGNX
On Monday, shares in Dublin, Ireland headquartered Shire PLC finished 0.35% higher at $151.80. A total volume of 1.24 million shares was traded, which was above their three months average volume of 1.02 million shares. The stock has advanced 4.96% in the last one month. The Company's shares are trading above their 50-day moving average by 3.70%. Additionally, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have an RSI of 59.53.
On December 01st, 2017, Shire announced that Andreas Busch, Ph.D. will join the Company as Executive Vice President, Head of R&D and Chief Scientific Officer, and will become a member of the Executive Committee, beginning January 2018. Howard Mayer, MD, currently serving as Head of Research and Development (ad interim), has been appointed Chief Medical Officer, also effective in January. Register now for your free research document on SHPG at: www.wallstequities.com/registration/?symbol=SHPG
Kenilworth, New Jersey headquartered Merck & Co. Inc.'s shares recorded a trading volume of 11.59 million shares at the end of yesterday's session, which was above their three months average volume of 11.48 million shares. The stock closed the day 0.04% lower at $56.22. The Company's shares have advanced 1.90% in the past month. The stock is trading below its 50-day moving average by 2.91%. Additionally, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 46.48.
On November 28th, 2017, research firm Bank of America/ Merrill resumed its 'Buy' rating on the Company's stock, with a target price of $64 per share.
On November 28th, 2017, Merck announced that its Board of Directors has increased the Company's quarterly dividend to $0.48 per outstanding share of common stock, up $0.01 from $0.47 per outstanding share paid last quarter. Payment will be made on January 08th, 2018, to stockholders of record at the close of business on December 15th, 2017. The Board also authorized an additional $10 billion of treasury stock purchases, with no time limit for completion. Click on the link below and see our free report MRK at: www.wallstequities.com/registration/?symbol=MRK
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-drug-makers-stocks----immune-pharmaceuticals-zogenix-shire-and-merck-300573057.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All